Borstkanker Onderzoek Groep

This study tests whether a combination of two hormone-targeting drugs (ribociclib and letrozole) can work as well as standard chemotherapy when given before surgery for a certain type of breast cancer. The trial involves 100 postmenopausal women with hormone receptor-positive, HE…

This study tests whether doctors can safely reduce the amount of chemotherapy given before surgery for HER2-positive breast cancer. By using medical imaging to monitor how the tumor responds, the goal is to give only as much chemo as needed. The study involves 462 participants wi…

This study tests a drug called trifluridine/tipiracil in 52 women with advanced ER-positive, HER2-negative breast cancer that has progressed after prior chemotherapy. The goal is to see if the drug can slow cancer growth and improve quality of life. Participants take the drug ora…

This study tests a combination of two drugs, fulvestrant and alpelisib, in people with a specific type of advanced breast cancer (HR+ HER2- with a PIK3CA mutation) whose disease has worsened while on fulvestrant alone. About 130 participants will continue fulvestrant and add alpe…

This study looks at the best time to add a CDK4/6 inhibitor to hormone therapy for women with advanced hormone-receptor-positive breast cancer. About 1,050 participants will either get the drug combination as their first treatment or wait until their second line of therapy. The g…